Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study intends to examine the effect of a commercially available nutritional supplement, Beta-hydroxy-beta-methylbutyrate(HMB) on whole-body responses to a sugar load.
One change associated with human aging is a reduction in "fitness", both in terms of how far or quickly a person can run/cycle/swim and also in how well their blood vessels work. Additionally a person's metabolic fitness decreases; this is how well the body copes with nutrition and is why, for example, older people have a higher risk of diseases like type 2 diabetes. Previous studies have shown that as people become less fit, they are at increased risk of suffering a complication whilst undergoing surgery. It has also been shown that measuring how fit someone is, is better at predicting the risk of a surgical complication than purely using a person's age alone. Lots of research has shown that exercise can potentially reverse some of the age-related declines in fitness, however most has used long sessions of continuous exercise over a long period of time. High-intensity interval training (HIT), whereby people cycle on an exercise bike very hard for a minute, followed by a short rest, repeated over the course of 15 minutes can rapidly improve a person's fitness. However not everyone will be able to, or indeed want to participate in exercise this strenuous; therefore this research seeks to explore whether other options, such as dietary supplements can improve aspects of fitness
This study intends to examine the effect of giving a dietary supplement on the way a person's body handles the glucose (from carbohydrates/ sugars) in a meal. Previous work has shown that taking a beta-hydroxy beta-methyl butyrate (HMB) supplement may improve may improve a patient's response to glucose, however the evidence is not clear. HMB is a commercially available nutritional supplement providing a compound that the body produces each time protein is consumed, and is most commonly used by bodybuilders to help gain muscle.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Older Men | Experimental | Healthy male adults aged 18-35 Subjects will receive both HMB and placebo on separate visits in a crossover fashion |
|
| Younger Men | Experimental | Healthy male adults aged 65-85 Subjects will receive both HMB and placebo on separate visits in a crossover fashion |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Beta-Hydroxy-Beta-Methylbutyrate | Dietary Supplement |
|
| |
| Measure | Description | Time Frame |
|---|---|---|
| Matsuda Index of insulin sensitivity | Assessed from arterialised venous blood samples | 180 minutes after a 75g oral glucose load |
| Cederholm index of insulin sensitivity | Assessed from arterialised venous blood samples | 180 minutes after a 75g oral glucose load |
| Measure | Description | Time Frame |
|---|---|---|
| Area-Under-Curve Glucose Concentration | Assessed from arterialised venous blood samples | 180 minutes after a 75g oral glucose load |
| Area-Under-Curve Insulin Concentration | Assessed from arterialised venous blood samples |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Current participation in a formal exercise regime
A BMI < 18 or > 32 kg·m2
Active cardiovascular disease:
o uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), Significant arrhythmia, right to left cardiac shunt, recent cardiac event
Taking beta-adrenergic blocking agents,
Cerebrovascular disease:
o previous stroke, aneurysm (large vessel or intracranial), epilepsy
Respiratory disease including:
o pulmonary hypertension, significant COPD, uncontrolled asthma,
Metabolic disease:
o hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, type 1 or 2 diabetes
Active inflammatory bowel or renal disease
Malignancy
Clotting dysfunction
Significant musculoskeletal or neurological disorders
Family history of early (<55y) death from cardiovascular disease
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Of Nottingham | Derby | DE22 3NE | United Kingdom |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 10480510 | Background | Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sep;22(9):1462-70. doi: 10.2337/diacare.22.9.1462. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C004961 | beta-hydroxyisovaleric acid |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Other |
|
| 180 minutes after a 75g oral glucose load |
| Femoral Artery Blood flow | Assessed using duplex ultrasonography of the superficial femoral artery of the right leg | 15 minutes, 60 minutes and 120 minutes after a 75g oral glucose load |